BeiGene Ltd (FRA:49BA)
€ 152 5 (3.4%) Market Cap: 15.89 Bil Enterprise Value: 14.28 Bil PE Ratio: 0 PB Ratio: 5.18 GF Score: 69/100

Beigene Ltd at Goldman Sachs Global Healthcare Conference Transcript

Jun 14, 2022 / 03:40PM GMT
Release Date Price: €123 (-11.51%)
Ziyi Chen
Goldman Sachs Group, Inc., Research Division - Equity Analyst

Great. Thank you for joining this session with BeiGene management team, and we're glad to have CFO, Julia; and Chief Business Executive, Angus, with us to discuss business -- recent business updates for BeiGene.

So before we get into any detailed questions, what about give us a recap about state of the business for now?

Julia Wang
BeiGene, Ltd. - CFO & Principal Accounting Officer

Of course, good morning. Thank you for having us, and we are delighted to be here. It is truly an exciting time to be at BeiGene right now. As a global science-based commercial stage and fully integrated biotech company, we now have over 8,500 colleagues, operating on 5 continents fighting against cancer.

The commercial team, in particular, has over 3,400 people operating in 9 of the 10 largest pharmaceutical markets, providing broader access to our medicines for the patients. And also last year, our total revenue was almost $1.2 billion.

Building upon the strong business

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot